| Followers | 53 |
| Posts | 14473 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Tuesday, September 30, 2025 1:32:43 PM
Taking it on the chin this afternoon. Funny because news of offering was out this morning so not sure if it is something else. Last earnings they claimed to have enough cash till 2028
Recent OCUL News
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026 • GlobeNewswire Inc. • 06/02/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:08:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:06:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2026 08:05:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:30:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:27:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:24:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:21:24 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 12:46:18 PM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/15/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/08/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 11:28:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:06:45 AM
- Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:23:14 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 09:17:14 PM
- Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026 • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:15:06 PM
- Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
